Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Trial Profile

Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2018

At a glance

  • Drugs CV 301 (Primary) ; MSB 0011359C (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2018 Planned End Date changed from 1 Jun 2020 to 1 Dec 2020.
    • 22 Sep 2018 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top